Legal & General Group PLC Theravance Biopharma, Inc. Transaction History

Legal & General Group PLC

  • $431 Billion
  • Q3 2025

A detailed history of Legal & General Group PLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 3,863 shares of TBPH stock, worth $67,177. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,863
Previous 4,140 6.69%
Holding current value
$67,177
Previous $45,000 24.44%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
SELL
$10.9 - $14.6 $3,019 - $4,044
-277 Reduced 6.69%
3,863 $56,000
Q2 2025

Aug 12, 2025
BUY
$8.32 - $11.25 $6,722 - $9,090
808 Added 24.25%
4,140 $45,000
Q1 2025

May 15, 2025
SELL
$8.44 - $10.47 $319,757 - $396,666
-37,886 Reduced 91.92%
3,332 $29,000
Q4 2024

Feb 13, 2025
SELL
$7.93 - $10.08 $174,491 - $221,800
-22,004 Reduced 34.8%
41,218 $387,000
Q3 2024

Feb 28, 2025
BUY
$7.66 - $10.25 $98,484 - $131,784
12,857 Added 31.19%
54,075 $435,000
Q2 2024

May 29, 2025
BUY
$8.29 - $9.92 $13,728 - $16,427
1,656 Added 3.16%
54,075 $458,000
Q2 2024

Aug 14, 2024
BUY
$8.29 - $9.92 $89,556 - $107,165
10,803 Added 20.61%
63,222 $536,000
Q1 2024

May 29, 2025
BUY
$8.22 - $11.59 $403,495 - $568,918
49,087 Added 1473.2%
52,419 $470,000
Q1 2024

May 14, 2024
BUY
$8.22 - $11.59 $16,645 - $23,469
2,025 Added 4.02%
52,419 $470,000
Q4 2023

May 29, 2025
BUY
$8.58 - $11.4 $403,791 - $536,506
47,062 Added 1412.42%
50,394 $566,000
Q4 2023

Feb 15, 2024
SELL
$8.58 - $11.4 $42,788 - $56,851
-4,987 Reduced 9.0%
50,394 $566,000
Q3 2023

Nov 14, 2023
SELL
$8.38 - $10.44 $15,209 - $18,948
-1,815 Reduced 3.17%
55,381 $477,000
Q2 2023

Aug 14, 2023
BUY
$10.16 - $11.92 $4,074 - $4,779
401 Added 0.71%
57,196 $591,000
Q1 2023

May 15, 2023
BUY
$9.87 - $11.44 $13,857 - $16,061
1,404 Added 2.53%
56,795 $616,000
Q4 2022

Feb 14, 2023
SELL
$9.65 - $11.34 $4,516 - $5,307
-468 Reduced 0.84%
55,391 $621,000
Q3 2022

Nov 14, 2022
SELL
$8.39 - $10.22 $25,547 - $31,119
-3,045 Reduced 5.17%
55,859 $566,000
Q2 2022

Aug 22, 2022
BUY
$8.41 - $10.34 $12,749 - $15,675
1,516 Added 2.64%
58,904 $534,000
Q1 2022

May 16, 2022
SELL
$8.33 - $12.96 $74 - $116
-9 Reduced 0.02%
57,388 $549,000
Q4 2021

Feb 14, 2022
BUY
$7.42 - $11.05 $108,688 - $161,860
14,648 Added 34.27%
57,397 $634,000
Q3 2021

Nov 15, 2021
BUY
$6.77 - $14.41 $75,986 - $161,737
11,224 Added 35.6%
42,749 $316,000
Q2 2021

Aug 12, 2021
BUY
$14.52 - $22.46 $6,693 - $10,354
461 Added 1.48%
31,525 $458,000
Q1 2021

May 17, 2021
SELL
$16.57 - $21.08 $3,330 - $4,237
-201 Reduced 0.64%
31,064 $634,000
Q3 2020

Nov 13, 2020
SELL
$14.79 - $22.49 $32,981 - $50,152
-2,230 Reduced 6.66%
31,265 $463,000
Q2 2020

Aug 14, 2020
SELL
$20.64 - $30.69 $10,175 - $15,130
-493 Reduced 1.45%
33,495 $703,000
Q1 2020

May 14, 2020
BUY
$17.84 - $31.21 $161,416 - $282,388
9,048 Added 36.28%
33,988 $785,000
Q4 2019

Feb 13, 2020
BUY
$16.12 - $25.89 $28,403 - $45,618
1,762 Added 7.6%
24,940 $646,000
Q3 2019

Nov 13, 2019
BUY
$16.51 - $23.78 $39,425 - $56,786
2,388 Added 11.49%
23,178 $452,000
Q2 2019

Aug 14, 2019
BUY
$15.6 - $25.15 $7,800 - $12,575
500 Added 2.46%
20,790 $339,000
Q1 2019

May 15, 2019
BUY
$22.57 - $28.15 $23,608 - $29,444
1,046 Added 5.44%
20,290 $460,000
Q4 2018

Feb 15, 2019
BUY
$22.52 - $35.07 $123,905 - $192,955
5,502 Added 40.04%
19,244 $492,000
Q2 2018

Aug 10, 2018
SELL
$22.06 - $25.52 $25,126 - $29,067
-1,139 Reduced 7.65%
13,742 $312,000
Q1 2018

May 17, 2018
SELL
$23.37 - $29.71 $146,272 - $185,954
-6,259 Reduced 29.61%
14,881 $361,000
Q4 2017

Feb 13, 2018
BUY
$25.82 - $35.66 $545,834 - $753,852
21,140
21,140 $591,000

Others Institutions Holding TBPH

# of Institutions
170
Shares Held
50.5M
Call Options Held
36.5K
Put Options Held
147K
View Full List

About Theravance Biopharma, Inc.

TBPH Quotes by TradingView
  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $1.16B
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email